Acorda Therapeutics Return on Tangible Equity 2006-2021 | ACOR

Current and historical return on tangible equity values for Acorda Therapeutics (ACOR) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Acorda Therapeutics Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2021-09-30 $-0.17B $-0.18B 106.75%
2021-06-30 $-0.13B $-0.16B 104.76%
2021-03-31 $-0.13B $-0.15B 115.86%
2020-12-31 $-0.10B $-0.13B 108.20%
2020-09-30 $0.05B $-0.06B -60.79%
2020-06-30 $-0.22B $-0.09B 222.67%
2020-03-31 $-0.23B $-0.08B 200.87%
2019-12-31 $-0.27B $-0.09B 212.04%
2019-09-30 $-0.33B $-0.13B 252.11%
2019-06-30 $-0.08B $-0.16B 62.45%
2019-03-31 $-0.01B $-0.14B 5.25%
2018-12-31 $0.03B $-0.10B -27.93%
2018-09-30 $-0.15B $-0.11B 100.51%
2018-06-30 $-0.16B $-0.11B 80.82%
2018-03-31 $-0.21B $-0.17B 83.88%
2017-12-31 $-0.22B $-0.20B 75.27%
2017-09-30 $-0.06B $-0.31B 16.33%
2017-06-30 $-0.04B $-0.34B 12.25%
2017-03-31 $-0.05B $-0.34B 14.90%
2016-12-31 $-0.04B $-0.36B 13.86%
2016-09-30 $-0.02B $-0.37B 13.90%
2016-06-30 $-0.01B $-0.35B 7.16%
2016-03-31 $0.01B $0.07B -148.57%
2015-12-31 $0.01B $-0.01B -25.73%
2015-09-30 $0.00B $-0.04B -3.39%
2015-06-30 $0.01B $-0.05B 12.90%
2015-03-31 $0.01B $-0.07B 6.61%
2014-12-31 $0.02B $-0.08B 5.35%
2014-09-30 $0.02B $0.51B 5.20%
2014-06-30 $0.02B $0.48B 4.35%
2014-03-31 $0.02B $0.43B 4.34%
2013-12-31 $0.02B $0.42B 3.98%
2013-09-30 $0.14B $0.41B 36.60%
2013-06-30 $0.15B $0.40B 42.01%
2013-03-31 $0.15B $0.38B 48.36%
2012-12-31 $0.16B $0.38B 59.77%
2012-09-30 $0.04B $0.24B 16.69%
2012-06-30 $0.05B $0.22B 22.30%
2012-03-31 $0.04B $0.21B 21.98%
2011-12-31 $0.03B $0.20B 19.02%
2011-09-30 $0.02B $0.18B 15.02%
2011-06-30 $0.02B $0.14B 11.41%
2011-03-31 $0.01B $0.13B 6.61%
2010-12-31 $-0.01B $0.13B -10.67%
2010-09-30 $-0.04B $0.12B -34.55%
2010-06-30 $-0.07B $0.10B -59.87%
2010-03-31 $-0.09B $0.10B -65.76%
2009-12-31 $-0.08B $0.12B -56.08%
2009-09-30 $-0.08B $0.14B -48.94%
2009-06-30 $-0.08B $0.16B -44.51%
2009-03-31 $-0.08B $0.18B -46.18%
2008-12-31 $-0.07B $0.19B -49.33%
2008-09-30 $-0.07B $0.21B -59.26%
2008-06-30 $-0.06B $0.10B -74.12%
2008-03-31 $-0.05B $0.11B -68.61%
2007-12-31 $-0.04B $0.05B -91.76%
2007-09-30 $-0.03B $0.06B -99.22%
2007-06-30 $-0.03B $0.06B -222.22%
2007-03-31 $-0.03B $0.00B 1000.00%
2006-12-31 $-0.06B $0.01B 1200.00%
2006-09-30 $-0.06B $-0.01B 168.00%
2006-06-30 $-0.07B $-0.01B 205.88%
2006-03-31 $-0.08B $-0.01B 262.50%
2005-12-31 $-0.05B $-0.12B 177.05%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.032B $0.153B
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09